Profile data is unavailable for this security.
About the company
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
- Revenue in USD (TTM)72.41m
- Net income in USD-6.57m
- Incorporated2001
- Employees107.00
- LocationSanara Medtech Inc1200 Summit Avenue, Suite 414FORT WORTH 76102United StatesUSA
- Phone+1 (817) 529-2300
- Websitehttps://sanaramedtech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procaps Group SA | 414.10m | 52.20m | 189.54m | 5.50k | 3.23 | 4.81 | 2.72 | 0.4577 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 189.63m | 100.00 | -- | 9.14 | -- | 9.41 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 190.72m | 76.00 | -- | 13.54 | -- | 83.08 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| Scilex Holding Co | 50.83m | -171.53m | 191.79m | 113.00 | -- | -- | -- | 3.77 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.22m | 195.59m | 3.00 | -- | 33.09 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 298.76m | -165.87m | 211.06m | 384.00 | -- | 0.8077 | -- | 0.7064 | -2.45 | -2.45 | 4.34 | 3.84 | 0.7605 | 3.69 | 15.91 | 778,026.10 | -42.22 | -- | -50.91 | -- | 84.64 | -- | -55.52 | -- | 4.66 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.74m | 232.14m | 1.00 | -- | 148.09 | -- | -- | -0.6855 | -0.6855 | 0.00 | 0.0529 | 0.00 | -- | -- | 0.00 | -467.16 | -- | -686.91 | -- | -- | -- | -- | -- | -- | -0.9299 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.85m | 1.63bn | 235.67m | 166.00 | 0.1343 | 1.07 | 0.144 | 127.18 | 121.21 | 121.21 | 0.0434 | 15.15 | 0.0079 | -- | 4.86 | 11,162.65 | 693.63 | -77.06 | 815.31 | -93.91 | -- | -- | 88,264.55 | -1,590.91 | -- | -21.96 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 242.11m | 147.00 | -- | -- | -- | 1.86 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Scpharmaceuticals Inc | 24.05m | -60.64m | 259.15m | 135.00 | -- | 20.24 | -- | 10.78 | -1.56 | -1.56 | 0.6187 | 0.256 | 0.2678 | 0.6563 | 6.23 | 178,133.30 | -67.52 | -38.23 | -75.77 | -42.31 | 71.15 | -- | -252.18 | -1,360.16 | 3.66 | -13.66 | 0.8121 | -- | -- | -- | -48.79 | -- | -- | -- |
| Sanara Medtech Inc | 72.41m | -6.57m | 280.87m | 107.00 | -- | 6.73 | -- | 3.88 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Precigen Inc | 4.39m | -135.38m | 284.12m | 202.00 | -- | 5.82 | -- | 64.73 | -0.5407 | -0.5407 | 0.0176 | 0.1709 | 0.0313 | -- | 4.71 | 21,727.72 | -96.46 | -31.50 | -119.34 | -38.63 | -13.56 | 44.00 | -3,084.55 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Esperion Therapeutics Inc | 277.79m | -98.50m | 329.66m | 240.00 | -- | -- | -- | 1.19 | -0.8758 | -0.8758 | 1.84 | -1.77 | 0.9466 | 0.7763 | 5.49 | 1,157,450.00 | -33.56 | -69.45 | -64.71 | -101.81 | 81.82 | -- | -35.46 | -147.44 | 1.49 | 0.0972 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.10bn | -587.00m | 353.83m | 1.60k | -- | 0.897 | -- | 0.321 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 391.87m | 99.00 | -- | 2.02 | -- | 6.32 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Data as of Sep 20 2024. Currency figures normalised to Sanara Medtech Inc's reporting currency: US Dollar USD
6.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 178.77k | 2.04% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 138.20k | 1.58% |
| Geode Capital Management LLCas of 30 Jun 2024 | 84.52k | 0.97% |
| Janney Montgomery Scott LLC (Investment Management)as of 30 Jun 2024 | 56.19k | 0.64% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 53.76k | 0.62% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 30.69k | 0.35% |
| World Investment Advisors LLCas of 30 Jun 2024 | 25.92k | 0.30% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 14.10k | 0.16% |
| Columbia Management Investment Advisers LLCas of 30 Jun 2024 | 13.15k | 0.15% |
| RBC Capital Markets LLC (Investment Management)as of 30 Jun 2024 | 11.89k | 0.14% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
